FindTrial
Sign In

Allogeneic CAR-T

BIOLOGICAL3 trials

Sponsors

The First Affiliated Hospital with Nanjing Medical University, Shanghai Zhongshan Hospital

Conditions

Autoimmune Diseases Refractory to Standard TherapiesB-cell Acute Lymphoblastic Leukemia (B-ALL)Graves DiseaseMature B-Cell LymphomaMultiple Myeloma (MM)Plasmablastic LymphomaRelapsed or Refractory B-cell Hematologic MalignanciesRelapsed or Refractory CD19+/BCMA+ Hematologic Malignancies

Early Phase 1

Allogeneic Anti-CD19 CAR-T for Refractory Graves' Disease
RecruitingNCT07129642
Shanghai Zhongshan HospitalGraves Disease
Start: 2025-08-10End: 2027-03-31Target: 5Updated: 2025-08-19

Phase 1

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
RecruitingNCT07105735
The First Affiliated Hospital with Nanjing Medical UniversityAutoimmune Diseases Refractory to Standard Therapies
Start: 2025-08-15End: 2027-12-01Target: 18Updated: 2026-09-01
RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
Not yet recruitingNCT07113496
The First Affiliated Hospital with Nanjing Medical UniversityB-cell Acute Lymphoblastic Leukemia (B-ALL), Mature B-Cell Lymphoma, Multiple Myeloma (MM) +3
Start: 2025-08-31End: 2027-12-31Target: 27Updated: 2025-08-13